Although RESCUE was not powered for clinical endpoints, it provided the rationale for the ongoing phase 3 ZEUS trial (NCT05021835), which is evaluating ziltivekimab in patients with CKD, high-sensitivity CRP ≥2 mg/L, and established atherosclerotic CVD, including stable CAD. This evidence concerns the gene CRP and coronary artery disorder.